The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

SureCN12200134     (3R,4S,5R)-2-[6- (cyclopentylamino)purin-9...

Synonyms: CHEBI:239526, AR-1K6724, AC1L2XT2, AC1Q4Y21, 41552-82-3, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of N6-Cyclopentyladenosine

 

Psychiatry related information on N6-Cyclopentyladenosine

  • Adenosine receptor agonists, including the selective A1 receptor agonist, N6-cyclopentyladenosine (CPA) and the A2A agonist, 2-[(2-aminoethylamino)carbonylethyl-phenylethylamino]- 5'-ethylcarboxa midoadenosine (APEC), reduced spontaneous motor activity in a dose-dependent manner [6].
 

High impact information on N6-Cyclopentyladenosine

 

Chemical compound and disease context of N6-Cyclopentyladenosine

 

Biological context of N6-Cyclopentyladenosine

  • Inasmuch as an A1-selective agonist N6-cyclopentyladenosine was less active, and the action of the A2-selective agonist CPCA was enhanced by an A2-receptor antagonist, we hypothesize that neither A1 or A2 receptors are involved in adenosine restoration of hrTNF-inhibited chemotaxis [16].
  • 5'(N-ethyl)carboxamidoadenosine (NECA), the most potent A2 receptor agonist, inhibited Fc gamma R-mediated phagocytosis and O2- generation, whereas N6-cyclopentyladenosine (CPA), a highly selective A1 receptor agonist, enhanced these functions [17].
  • N6-Cyclopentyladenosine (CPA), an A1 receptor agonist, did not activate Ca(2+)-related signal transduction systems by itself but instead inhibited cAMP accumulation [18].
  • In this study, desensitization and down-regulation of A1 adenosine receptors (A1AR) by the allosteric enhancer PD81,723 (PD) and by N6-cyclopentyladenosine (CPA) were investigated after 24-hr pretreatment of CHO-K1 cells stably expressing recombinant human A1AR [19].
  • This GTP shift appeared indicative for partial agonism in vivo, since the N6-cyclopentyladenosine derivatives showed lower intrinsic activities than the prototypic full agonist N6-cyclopentyladenosine on the decrease in heart rate in conscious, normotensive rats [20].
 

Anatomical context of N6-Cyclopentyladenosine

 

Associations of N6-Cyclopentyladenosine with other chemical compounds

 

Gene context of N6-Cyclopentyladenosine

 

Analytical, diagnostic and therapeutic context of N6-Cyclopentyladenosine

References

  1. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Matherne, G.P., Linden, J., Byford, A.M., Gauthier, N.S., Headrick, J.P. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  2. A role of protein kinase C mu in signalling from the human adenosine A1 receptor to the nucleus. Hill, K.J., Webber, A.C., Hill, S.J. Br. J. Pharmacol. (2003) [Pubmed]
  3. Synergy between the inositol phosphate responses to transfected human adenosine A1-receptors and constitutive P2-purinoceptors in CHO-K1 cells. Megson, A.C., Dickenson, J.M., Townsend-Nicholson, A., Hill, S.J. Br. J. Pharmacol. (1995) [Pubmed]
  4. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. Wiesner, J.B., Ugarkar, B.G., Castellino, A.J., Barankiewicz, J., Dumas, D.P., Gruber, H.E., Foster, A.C., Erion, M.D. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  5. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Young, D., Dragunow, M. Neuroscience (1994) [Pubmed]
  6. Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. Marston, H.M., Finlayson, K., Maemoto, T., Olverman, H.J., Akahane, A., Sharkey, J., Butcher, S.P. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  7. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. Libert, F., Schiffmann, S.N., Lefort, A., Parmentier, M., Gérard, C., Dumont, J.E., Vanderhaeghen, J.J., Vassart, G. EMBO J. (1991) [Pubmed]
  8. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Green, P.G., Basbaum, A.I., Helms, C., Levine, J.D. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  9. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Giannella, E., Mochmann, H.C., Levi, R. Circ. Res. (1997) [Pubmed]
  10. Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells: differential involvement of adenosine. Liu, J., Tian, Z., Gao, B., Kunos, G. J. Biol. Chem. (2002) [Pubmed]
  11. Role of adenosine in insulin-stimulated release of leptin from isolated white adipocytes of Wistar rats. Cheng, J.T., Liu, I.M., Chi, T.C., Shinozuka, K., Lu, F.H., Wu, T.J., Chang, C.J. Diabetes (2000) [Pubmed]
  12. Distinct KATP channels mediate the antihypertrophic effects of adenosine receptor activation in neonatal rat ventricular myocytes. Xia, Y., Javadov, S., Gan, T.X., Pang, T., Cook, M.A., Karmazyn, M. J. Pharmacol. Exp. Ther. (2007) [Pubmed]
  13. Comparison of the ability of adenosine kinase inhibitors and adenosine receptor agonists to attenuate thermal hyperalgesia and reduce motor performance in rats. Jarvis, M.F., Mikusa, J., Chu, K.L., Wismer, C.T., Honore, P., Kowaluk, E.A., McGaraughty, S. Pharmacol. Biochem. Behav. (2002) [Pubmed]
  14. Clearance of cyclopentyladenosine and cyclohexyladenosine in rats following a single subcutaneous dose. Tuovinen, K., Tarhanen, J. Pharmacol. Res. (2004) [Pubmed]
  15. Age-related changes in adenosine in rat coronary resistance vessels. Rose'Meyer, R.B., Harden, F.A., Varela, J.I., Harrison, G.J., Willis, R.J. Gen. Pharmacol. (1999) [Pubmed]
  16. Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration: implication of a novel cyclic AMP-independent action on the cell surface. Sullivan, G.W., Linden, J., Hewlett, E.L., Carper, H.T., Hylton, J.B., Mandell, G.L. J. Immunol. (1990) [Pubmed]
  17. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. Salmon, J.E., Cronstein, B.N. J. Immunol. (1990) [Pubmed]
  18. A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Akbar, M., Okajima, F., Tomura, H., Shimegi, S., Kondo, Y. Mol. Pharmacol. (1994) [Pubmed]
  19. Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors. Bhattacharya, S., Linden, J. Mol. Pharmacol. (1996) [Pubmed]
  20. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors. Roelen, H., Veldman, N., Spek, A.L., von Frijtag Drabbe Künzel, J., Mathôt, R.A., IJzerman, A.P. J. Med. Chem. (1996) [Pubmed]
  21. Purification of A1 adenosine receptor-G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling. Gao, Z., Robeva, A.S., Linden, J. Biochem. J. (1999) [Pubmed]
  22. Slowing of shortening velocity of rat cardiac myocytes by adenosine receptor stimulation regardless of beta-adrenergic stimulation. Strang, K.T., Mentzer, R.M., Moss, R.L. J. Physiol. (Lond.) (1995) [Pubmed]
  23. Binding of the adenosine A2 receptor ligand [3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. Wan, W., Sutherland, G.R., Geiger, J.D. J. Neurochem. (1990) [Pubmed]
  24. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. Sarges, R., Howard, H.R., Browne, R.G., Lebel, L.A., Seymour, P.A., Koe, B.K. J. Med. Chem. (1990) [Pubmed]
  25. Circulating triglyceride lipolysis facilitates lipoprotein lipase translocation from cardiomyocyte to myocardial endothelial lining. Pulinilkunnil, T., Qi, D., Ghosh, S., Cheung, C., Yip, P., Varghese, J., Abrahani, A., Brownsey, R., Rodrigues, B. Cardiovasc. Res. (2003) [Pubmed]
  26. Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. Ferré, S., Torvinen, M., Antoniou, K., Irenius, E., Civelli, O., Arenas, E., Fredholm, B.B., Fuxe, K. J. Biol. Chem. (1998) [Pubmed]
  27. Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Cordeaux, Y., Briddon, S.J., Megson, A.E., McDonnell, J., Dickenson, J.M., Hill, S.J. Mol. Pharmacol. (2000) [Pubmed]
  28. Pharmacological manipulations of ATP-dependent potassium channels and adenosine A1 receptors do not impact hippocampal ischemic preconditioning in vivo: evidence in a highly quantitative gerbil model. Sorimachi, T., Nowak, T.S. J. Cereb. Blood Flow Metab. (2004) [Pubmed]
  29. The effects of elevated cyclic AMP levels on histamine-H1-receptor-stimulated inositol phospholipid hydrolysis and calcium mobilization in the smooth-muscle cell line DDT1MF-2. Dickenson, J.M., White, T.E., Hill, S.J. Biochem. J. (1993) [Pubmed]
  30. The endothelium of the rat renal artery plays an obligatory role in A2 adenosine receptor-mediated relaxation induced by 5'-N-ethylcarboxamidoadenosine and N6-cyclopentyladenosine. Martin, P.L., Potts, A.A. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  31. p38 Mitogen-Activated Protein Kinase Contributes to Adenosine A1 Receptor-Mediated Synaptic Depression in Area CA1 of the Rat Hippocampus. Brust, T.B., Cayabyab, F.S., Zhou, N., Macvicar, B.A. J. Neurosci. (2006) [Pubmed]
  32. Synergistic interactions between human transfected adenosine A1 receptors and endogenous cholecystokinin receptors in CHO cells. Dickenson, J.M., Hill, S.J. Eur. J. Pharmacol. (1996) [Pubmed]
  33. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Schindler, C.W., Karcz-Kubicha, M., Thorndike, E.B., Müller, C.E., Tella, S.R., Ferré, S., Goldberg, S.R. Br. J. Pharmacol. (2005) [Pubmed]
  34. Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK. Liu, Q., Hofmann, P.A. Am. J. Physiol. Heart Circ. Physiol. (2003) [Pubmed]
  35. Activation of protein kinase B by the A(1)-adenosine receptor in DDT(1)MF-2 cells. Germack, R., Dickenson, J.M. Br. J. Pharmacol. (2000) [Pubmed]
  36. Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons. Brand, A., Vissiennon, Z., Eschke, D., Nieber, K. Neuropharmacology (2001) [Pubmed]
  37. Mechanisms mediating regional sympathoactivatory responses to stimulation of NTS A(1) adenosine receptors. Scislo, T.J., O'Leary, D.S. Am. J. Physiol. Heart Circ. Physiol. (2002) [Pubmed]
  38. Adenosine A(1)-receptor induced late preconditioning and myocardial infarction: reperfusion duration is critical. Tissier, R., Souktani, R., Bruneval, P., Giudicelli, J.F., Berdeaux, A., Ghaleh, B. Am. J. Physiol. Heart Circ. Physiol. (2002) [Pubmed]
  39. Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action. Bueters, T.J., van Helden, H.P., IJzerman, A.P., Danhof, M. Neurosci. Lett. (2003) [Pubmed]
  40. Ontogeny of adenosine receptors in the longitudinal muscle and muscularis mucosae of the rat distal colon. Peachey, J.A., Hourani, S.M., Kitchen, I. Naunyn Schmiedebergs Arch. Pharmacol. (1999) [Pubmed]
 
WikiGenes - Universities